Oxford Nanopore Technologies plc New infectious disease partnership with bioMerieux

TIDMONT

Oxford Nanopore Technologies plc

17 April 2023

Oxford Nanopore and bioMérieux

to enter into a strategic partnership agreement

to develop innovative infectious disease diagnostics

Oxford, UK and Marcy-l'Etoile, France, 17 April 2023: Oxford Nanopore Technologies plc (LSE: ONT) ("Oxford Nanopore"), the company delivering a new generation of nanopore-based molecular sensing technology, and bioMérieux SA, a world leader in the field of in vitro diagnostics, announced that they have teamed up to improve health outcomes globally by exploring selected opportunities to bring nanopore sequencing to the infectious disease diagnostics market.

The companies are jointly exploring selected opportunities to advance patient care by providing access to nanopore-based clinical research and in vitro diagnostic (IVD) solutions.

Nanopore-based sequencing is a novel technology that enables analysis of long DNA or RNA fragments. It works by monitoring changes to an electrical current as nucleic acids are passed through a protein nanopore. The resulting signal is decoded to provide the specific DNA or RNA sequence. The unique real-time, scalable features of this technology make it ideal for the rapid and cost-effective characterisation of pathogens in clinical samples.

Offering rapid and accurate identification of microbial pathogens and associated antimicrobial resistance, Oxford Nanopore is uniquely positioned to deliver nanopore-based sequencing solutions that provide comprehensive results and reduce time to results for infectious diseases research and diagnostic applications.

Initial areas of collaboration will include a test for determining antibiotic resistance of tuberculosis; an assay to identify pathogens in normally sterile clinical samples; and validating Oxford Nanopore's sequencing platform with BIOMÉRIEUX EPISEQ(R) CS application for rapid infection outbreak monitoring in patient-care settings.

Gordon Sanghera, Oxford Nanopore Technologies Chief Executive Officer, commented: "We are pleased to partner with bioMérieux's IVD expertise to add powerful new tools for the fight against infectious disease. By offering rapid and accurate identification of pathogens and associated antimicrobial resistance, at scale, we hope to better equip the specialists for whom speed and access to comprehensive data is key."

Alexandre Mérieux, bioMérieux Chairman and CEO, commented: "We are excited to enter into a research partnership with Oxford Nanopore in the field of infectious diseases. New technologies such as sequencing hold promise to improve diagnostics and patient care; our teams will collaborate in this direction."

[ENDS]

About Oxford Nanopore Technologies plc:

Oxford Nanopore Technologies' goal is to bring the widest benefits to society through enabling the analysis of anything, by anyone, anywhere. The company has developed a new generation of nanopore-based sensing technology that is currently used for real-time, high-performance, accessible, and scalable analysis of DNA and RNA. The technology is used in more than 120 countries, to understand the biology of humans, plants, animals, bacteria, viruses and environments as well as to understand diseases such as cancer. Oxford Nanopore's technology also has the potential to provide broad, high impact, rapid insights in a number of areas including healthcare, food and agriculture. For more information please visit: www.nanoporetech.com

About bioMérieux:

PIONEERING DIAGNOSTICS

A world leader in the field of in vitro diagnostics since 1963, bioMérieux is present in 45 countries and serves more than 160 countries with the support of a large network of distributors. In 2022, revenues reached EUR3.6 billion, with over 90% of sales outside of France. bioMérieux provides diagnostic solutions (systems, reagents, software and services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in food, pharmaceutical and cosmetic products. Learn more: www.biomerieux.com

 
  bioMérieux is listed on the Euronext Paris stock market. 
   Symbol: BIM - ISIN Code: FR0013280286 
   Reuters: BIOX.PA/Bloomberg: BIM.FP 
 

CONTACTS

 
 
 Oxford Nanopore 
 Media Relations          Teneo (communication adviser to the 
                           Company) 
 [e-mail]   Tom Murray, Olivia Peters 
                          Tel.: [phone] 
   Investor Relations 
 [e-mail]      [e-mail] 
 
 
 bioMérieux 
 Media Relations        Investor Relations 
 Romain Duchez          Franck Admant 
 Tel.: [phone]   Tel.: [phone] 
  21 99 
 [e-mail]   [e-mail] 
 
 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAIFMMTMTMBTFJ

(END) Dow Jones Newswires

April 17, 2023 02:00 ET (06:00 GMT)